OTCMKTS:GNMSF Genmab A/S (GNMSF) Stock Price, News & Analysis $220.09 +14.99 (+7.31%) As of 05/2/2025 11:40 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Genmab A/S Stock (OTCMKTS:GNMSF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genmab A/S alerts:Sign Up Key Stats Today's Range$208.95▼$220.0950-Day Range$178.74▼$240.0052-Week Range$170.00▼$305.09Volume6 shsAverage Volume3,022 shsMarket Capitalization$14.54 billionP/E Ratio12.56Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More… Genmab A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreGNMSF MarketRank™: Genmab A/S scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Genmab A/S. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 12.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 12.56, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.79.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.11% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Genmab A/S has recently increased by 30.12%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.11% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Genmab A/S has recently increased by 30.12%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.08 News SentimentGenmab A/S has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Genmab A/S this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Read more about Genmab A/S's insider trading history. Receive GNMSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address GNMSF Stock News HeadlinesIs Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now?May 1 at 4:04 AM | insidermonkey.comGenmab Continues Share Buy-back Program in April 2025April 28, 2025 | tipranks.comAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.May 4, 2025 | Paradigm Press (Ad)Genmab Advances Share Buy-back Program with Significant TransactionsApril 14, 2025 | tipranks.comGenmab A/S Updates Articles of Association to Enhance Capital FlexibilityApril 10, 2025 | tipranks.comGenmab A/S Share Capital ReductionApril 10, 2025 | investing.comGenmab A/S Advances Share Buy-back Program as of April 2025April 7, 2025 | tipranks.comIs Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?April 2, 2025 | insidermonkey.comSee More Headlines GNMSF Stock Analysis - Frequently Asked Questions How have GNMSF shares performed this year? Genmab A/S's stock was trading at $207.38 at the start of the year. Since then, GNMSF stock has increased by 6.1% and is now trading at $220.0875. View the best growth stocks for 2025 here. How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) released its earnings results on Wednesday, February, 12th. The company reported $5.70 EPS for the quarter, topping the consensus estimate of $0.46 by $5.24. Genmab A/S had a net margin of 36.30% and a trailing twelve-month return on equity of 19.75%. How do I buy shares of Genmab A/S? Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/12/2025Today5/04/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:GNMSF CIK1434265 Webwww.genmab.com Phone(457) 020-2728Fax45-7020-2729Employees1,660Year Founded1999Profitability EPS (Most Recent Fiscal Year)$17.52 Trailing P/E Ratio12.56 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.14 billion Net Margins36.30% Pretax Margin42.57% Return on Equity19.75% Return on Assets16.23% Debt Debt-to-Equity RatioN/A Current Ratio5.25 Quick Ratio5.24 Sales & Book Value Annual Sales$3.12 billion Price / Sales4.66 Cash Flow$14.98 per share Price / Cash Flow14.69 Book Value$80.53 per share Price / Book2.73Miscellaneous Outstanding Shares66,075,000Free Float65,057,000Market Cap$14.54 billion OptionableNot Optionable Beta1.10 Social Links Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:GNMSF) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.